Neuropsychopharmacology
2023
Abigail E. Calder, Gregor Hasler
303 citations
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and addiction. Importantly, clinical improvements can last for months or years after treatment. It has been theorized that these long-term improvements arise because psychedelics rapidly and lastingly stimulate neuroplasticity. The focus of this review is...
Journal of Psychoactive Drugs
2023
Zachary Herrmann, Mitch Earleywine, Joseph A. de Leo et al.
19 citations
Subjective responses to psychoactive drugs have served as intriguing windows into consciousness as well as useful predictors. Subjective reactions to psychedelic molecules are particularly interesting given how they covary with subsequent improvements associated with psychedelic-assisted treatments. Although links between subjective reactions and decreases in treatment-resistant clinical...
European Neuropsychopharmacology
2023
Lucas Oliveira Maia, Dimitri Daldegan-Bueno, Isabel Wießner et al.
46 citations
The therapeutic potential of the psychedelic brew ayahuasca has been investigated in preclinical and clinical studies. Currently, the most consistent evidence refers to depression. However, various studies suggest that ayahuasca may comprise therapeutic benefits in other health conditions. This narrative review provides a comprehensive, up-to-date overview of ayahuasca's therapeutic effects in...
Psychopharmacology
2023
Juliet Meccia, Joëlle Lopez, Rosemary C. Bagot
14 citations
Interest in the therapeutic potential of serotonergic psychedelic compounds including psilocybin has surged in recent years. While human clinical research suggests psilocybin holds promise as a rapid and long-lasting antidepressant, little is known about how its acute mechanisms of action mediate enduring alterations in cognition and behavior. Human neuroimaging studies point to both acute and...
Perspectives in biology and medicine
2023
Gail A. Edelsohn, Dominic Sisti
8 citations
Recent clinical trials of psychedelic drugs aim to treat a range of psychiatric conditions in adults. MDMA and psilocybin administered with psychotherapy have received FDA designation as "breakthrough therapies" for post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD) respectively. Given the potential benefit for minors burdened with many of the same disorders, calls...
Journal of Psychopharmacology
2023
Jack E Henningfield, Judy Ashworth, David J Heal et al.
13 citations
Background: Psychedelics are an increasingly active area of research and pharmaceutical development. This includes abuse potential assessment to better understand their pharmacological mechanisms and effects and guide controlled substance regulation. Psychedelics pose challenges to abuse assessments to ensure valid, reliable, and generalizable outcomes and safe study conduct. Findings: Key...
Frontiers in Psychiatry
2023
Deborah Rudin, Alexander Areesanan, Matthias E. Liechti et al.
9 citations
Classic psychedelics have been shown to exert therapeutic potential for the treatment of various psychiatric disorders, neuropsychiatric diseases, and neuronal damage. Besides their psychopharmacological activity, psychedelics have been reported to modulate immune functions. There has thus far been a sparse exploration of the direct immune-modulating effect of psychedelics on human immune cells...
Frontiers in Pharmacology
2023
Kateřina Syrová, Klára Šíchová, Hynek Danda et al.
4 citations
Introduction: N-2-methoxy-benzylated ("NBOMe") analogues of phenethylamine are a group of new psychoactive substances (NPS) with reported strong psychedelic effects in sub-milligram doses linked to a number of severe intoxications, including fatal ones. In our present work, we provide a detailed investigation of pharmacokinetics and acute behavioural effects of 2C-B-Fly-NBOMe...
Neuroscience of Consciousness
2023
Sidath Rankaduwa, Adrian M. Owen
21 citations
Given their recent success in counseling and psychiatry, the dialogue around psychedelics has mainly focused on their applications for mental health. Insights from psychedelic research, however, are not limited to treating mental health, but also have much to offer our current understanding of consciousness. The investigation of psychedelic states has offered new perspectives on how different...
Frontiers in Neuroscience
2023
Azat Nasretdinov, Sebastian A Barrientos, Ivani Brys et al.
6 citations
Psychedelic substances have in recent years attracted considerable interest as potential treatments for several psychiatric conditions, including depression, anxiety, and addiction. Imaging studies in humans point to a number of possible mechanisms underlying the acute effects of psychedelics, including changes in neuronal firing rates and excitability as well as alterations in functional...